We should not be using obesity pharmacotherapy or surgery in those who do not have the disease of obesity and thus the benefits will outweigh any of those risks if utilized in the indicated patient population.
When levels are low, signals do not travel as efficiently, which can lead to these strange sensations
Don't use revenue code 260 (IV Solutions) for subcutaneous or intramuscular injections
Think of GLP-1 as your body's "meal manager." The moment you start eating, your gut starts releasing this hormone
Finally, In a recent meta-analysis on 56,004 patients from 7 CVOTs (68.9% patients with established cardiovascular disease), GLP-1RAs reduced the risk of MACE by 13%, of cardiovascular death by 12%, of all-cause mortality by 11%, of non-fatal stroke by 16%, of hospitalization for heart failure by 9%, of macroalbuminuria by 24% [13]